Cabaletta Bio Reports Third-Quarter 2026 Results, Updates RESET-Myositis Timeline
Cabaletta Bio said RESET-Myositis registrational adult topline results are anticipated in 2H27, with a BLA submission in 1Q28.
Story updates
12:32:59 PM UTC
SquawkNews
Cabaletta Bio reported $299.4M in cash as of September 30, 2026, and said its operational runway extends into 1Q28. It expects RESET-Myositis topline results in 2H27 and plans a BLA submission in 1Q28.Material DetailsContext by AI AnalystThis is a mid-cycle clinical-stage update, with the company a…